Trial Search Results

Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia

A lung condition called bronchopulmonary dysplasia (BPD) is a major cause of poor outcomes and death for premature infants. Infants with BPD are also at high risk for pulmonary hypertension (PH)—an important contributor to their condition. Previous research has suggested that a protein in the blood, endothelin-1 (ET-1), is associated with pulmonary disease.

This study aims to investigate the incidence of PH and levels of ET-1 among premature babies with BPD. It will also potentially allow us to focus further research efforts and treatment towards these infants, some of our sickest patients at LPCH.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - Premature Infants (<30 weeks EGA)

Exclusion Criteria:

   - Major congenital malformations (cardiac, respiratory, gastrointestinal)

   - congenital infection, and/or

   - known genetic syndromes (i.e. trisomy 21)

Ages Eligible for Study

N/A - 30 Weeks

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christine Johnson, MD
650 723-5711
Not Recruiting